Abstract 1776
Background
Mobile phones and tablets currently represent a significant presence in people’s everyday lives. They enable access to different information and services independent of current place and time. Such widespread connectivity offers significant potential in different app areas including health care. Advancements in mobile technology allow innovative data collection techniques such as measuring time use for the purpose of improving health behavior change interventions.
Methods
The aim of this study is to examine the usage rates of healthcare users and the health content of applications. A total of 707 mobile app were retrieved through a Google and App store for app published between January to April 2019. In this context, all applications were scanned using "cancer", "oncology", and "breast cancer" keywords on these stores. Repetitive applications were removed and research data was obtained. The applications were evaluated by considering their contents, developers and download numbers.
Results
In the Google play store, under the training title of 268 applications, it was found that 76 applications were used to maintain the treatment scheme and plan, and 12 were used for communication purposes. In the app store, it was determined that 235 applications were used for education, 102 for treatment plan and order, and 14 for communication purposes. Educational applications were used for journal, congress, student information, cancer guidelines and patient information. Drug management for treatment regimen and plan was determined to be related to radiological imaging, diet follow-up, symptoms, and nutrition. It was seen that communication applications were used for both patient-patient and physician-patient interaction. It was found that only 8% of the existing applications that the majority of the application developers did not have a healthcare staff established a health care staff.
Conclusions
It can be said that health personnel develop their own systems and provide accurate information to patients through these systems. With the advancement of health technologies, healthy results can be obtained in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract